Brazil Pharma Diabetes and Weight-Loss Drugs

The Brazilian market for weight-loss treatments is seeing rapid demand expansion, led by GLP1 weight-loss pens and treatments like Ozempic (semaglutide). In 2024, the market generated US $188.6 million and is projected to reach US $531.5 million by 2030. With the upcoming expiration of Ozempic’s patent in March 2026, consumers are expecting lower prices from increased competition.  

The Brazilian Government has launched initiatives to research and implement GLP-1 treatments to combat obesity through the public health system.  Additionally, Brazil’s expanding private healthcare and employer wellness markets present openings for value-based care models and integrated obesity management strategies.  

Local production has ramped up to meet demand. For example, Brazilian pharmaceutical company EMS has invested over R$1 billion (approximately US$200 million) in local peptide production and launched its first GLP-1 pen in August 2025. Novo Nordisk is also investing locally. The company is investing approximately US$1.1 billion (R$6.4 billion) to increase production for both the Brazilian and global markets at its facility in Minas Gerais.  

There is also growing demand for clinical trial collaborations and digital health solutions that complement GLP-1 therapies. This further presents U.S. companies with strong opportunities in Brazil through biosimilar licensing, manufacturing partnerships, and technology transfer agreements.  

For additional information on opportunities in the semaglutide generic market in Brazil, please contact:
Jefferson Oliveira, Healthcare Commercial Specialist, 
U.S. Embassy Brazil, Sao Paulo Office
Jefferson.Oliveira@trade.gov